Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00055653
- Locations
- ๐บ๐ธ
Children's Hospital Los Angeles, Los Angeles, California, United States
๐บ๐ธChildren's Hospital of Orange County, Orange, California, United States
๐บ๐ธNorth Shore University Hospital, Manhasset, New York, United States
Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic Leukemia
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 1
- Registration Number
- NCT00054171
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors
Phase 1
Completed
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00054288
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer Who Have Undergone Surgery or Radiation Therapy
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2011-03-08
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT00054522
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
๐บ๐ธHillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT00054158
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
Phase 2
Completed
- Conditions
- Interventions
- Biological: anti-thymocyte globulinBiological: graft-versus-tumor induction therapyBiological: sargramostimBiological: therapeutic allogeneic lymphocytesDrug: cyclophosphamideDrug: fludarabine phosphateDrug: methylprednisoloneDrug: mycophenolate mofetilDrug: tacrolimusProcedure: allogeneic bone marrow transplantationProcedure: peripheral blood stem cell transplantationProcedure: umbilical cord blood transplantation
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 41
- Registration Number
- NCT00053989
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2011-03-01
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT00054002
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00054314
Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
Phase 1
Completed
- Conditions
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2011-03-08
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00053144
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT00053157
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath